Latest Spinogenix News & Updates

See the latest news and media coverage for Spinogenix. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Spinogenix

Synaptic regenerative therapeutics for brain disorders

spinogenix.com
Headquarters
Los Angeles, United States
Founded year
2016
Company type
Private company
Number of employees
4–10

Latest news about Spinogenix

Company announcements

  • Spinogenix

    Spinogenix founder speaks at symposium

    Stella Sarraf shares her journey and Spinogenix's progress in synapse regeneration for ALS, Alzheimer’s, schizophrenia, and Fragile X, with positive trial readouts.

  • Spinogenix

    Spinogenix announces CLARITY Phase 2b/3 trial

    It will evaluate oral SPG601 in male Fragile X patients, assessing EEG biomarkers and cognitive outcomes across dose regimens.

  • Spinogenix

    Spinogenix announces peer-reviewed research on SPG601 efficacy in FXS

    Phase 2 trial shows SPG601 reduces gamma band activity, improves cognition, and is well-tolerated. Published in Nature Scientific Reports.

  • Spinogenix

    Spinogenix reports early Phase 2 improvements for tazbentetol in schizophrenia

    Interim analysis demonstrates favorable safety, PANSS score reductions, and EEG biomarker improvements versus placebo at SIRS 2026 Congress.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Spinogenix

Track Spinogenix and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Spinogenix competitors & trending companies

Browse news for competitors to Spinogenix and other trending companies.